Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Generali

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|November 17, 2001
Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancerA Bottini, A Berruti, A Bersiga, et al.
Endocrine-Related Cancer|June 11, 2005
Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trialA Bottini, A Berruti, M P Brizzi, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 15, 2020
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET populationE Ciruelos, G Jerusalem, M Martin, et al.
Molecular Biology Reports|March 7, 2019
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesotheliomaN Sobhani, G Roviello, T Pivetta, et al.
British Journal of Cancer|May 29, 2008
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastasesD Generali, A Dovio, M Tampellini, et al.
Breast Cancer Research and Treatment|April 5, 2017
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.
Breast Cancer Research and Treatment|March 15, 2017
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.
British Journal of Cancer|May 31, 2014
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatmentD Generali, F M Buffa, S Deb, et al.
British Journal of Cancer|April 12, 2014
Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagyM I Koukourakis, A Giatromanolaki, A Bottini, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 4, 2020
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatmentA Ianza, F Giudici, C Pinello, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|November 17, 2001
Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancerA Bottini, A Berruti, A Bersiga, et al.
Endocrine-Related Cancer|June 11, 2005
Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trialA Bottini, A Berruti, M P Brizzi, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 15, 2020
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET populationE Ciruelos, G Jerusalem, M Martin, et al.
Molecular Biology Reports|March 7, 2019
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesotheliomaN Sobhani, G Roviello, T Pivetta, et al.
British Journal of Cancer|May 29, 2008
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastasesD Generali, A Dovio, M Tampellini, et al.
Breast Cancer Research and Treatment|April 5, 2017
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.
Breast Cancer Research and Treatment|March 15, 2017
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.
British Journal of Cancer|May 31, 2014
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatmentD Generali, F M Buffa, S Deb, et al.
British Journal of Cancer|April 12, 2014
Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagyM I Koukourakis, A Giatromanolaki, A Bottini, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 4, 2020
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatmentA Ianza, F Giudici, C Pinello, et al.
Pageof 6